Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
16 Setembro 2024 - 5:05PM
Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a
clinical-stage biopharmaceutical company developing novel
therapeutics for the treatment of rare diseases, today announced
that management will present at the 2024 Cantor Global Healthcare
Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
A live audio webcast and replay of the presentation will be
available in the Investors section on the Company’s website at
www.soleno.life.
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. An NDA for its
lead candidate, DCCR (diazoxide choline) extended-release tablets,
a once-daily oral tablet for the treatment of Prader-Willi syndrome
(PWS) is currently under review by the FDA and was granted Priority
Review. For more information, please visit www.soleno.life.
Corporate Contact:Brian RitchieLifeSci
Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024